Earnings Call · Q2 FY2022·2022-08-02

Q2 22EPS -14.13%·Rev n/aQ1 22EPS +10.58%·Rev n/aQ4 21EPS +22.03%·Rev n/aQ3 21EPS +6.43%·Rev n/a⚠ consensus missing

Esperion Therapeutics, Inc. ESPR

Tiffany Aldrich — Corporate Communications

Sheldon Koenig — President and CEO

+7.7%1d on move date+8.4% vs SPY3d+8.6%5d+17.8%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ESPR calls or request research access.

More ESPR calls Browse calls Request research access